^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Published date:
05/25/2023
Excerpt:
A significant improvement in OS was observed for the toripalimab arm over the placebo arm: HR=0.73 (95% CI: 0.57-0.93), two-sided p=0.0108, median OS 23.8 vs 17.0 months. A consistent effect on OS, favoring the toripalimab arm, was observed all PD-L1 expression subgroups....The addition of toripalimab to chemotherapy in patients with advanced NSCLC provided significant OS benefit than chemotherapy alone with a manageable safety profile.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2023.41.16_suppl.9003
Trial ID:
Source:
Title:
The study of Triprilimab therapy with cytokine induced killer cells in advanced non-small cell lung cancer
Excerpt:
...Before randomization, patients must have PD-L1 positive tumor cells (defined as PD-L1 expression in >=1% of tumor tissues by the reference laboratory using Ventana sp263 PD-L1 IHC test results). ...
Trial ID:
Source:
Title:
Clinical study of mRNA personalized tumor vaccine encoding neoantigen combined with toripalimab injection in the treatment of advanced non-small cell lung cancer
Excerpt:
...(1) Cohort A: Non-small cell lung cancer patients with secondary drug resistance after PD-1/PD-L1 drug therapy (The first dose of toripalimab in this trial was >= 6 months from the last PD-1/PD-L1 drug administration); (2) Cohort B: patients who are not PD-L1-positive and non-small cell lung cancer patients who have not been treated with PD-1/PD-L1 drugs; 5. ...
Trial ID:
More C2 evidence
Source:
Title:
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Excerpt:
...Major Pathologic Response (MPR) Rate`Pathologic Complete Response (pCR) Rate in non-squamous NSCLC with different EGFR mutations status`Major Pathologic Response (MPR) Rate in non-squamous NSCLC with different EGFR mutations status`Pathologic Complete Response (pCR) Rate in non-squamous NSCLC with different PD-L1 expression levels`Major Pathologic Response (MPR) Rate in non-squamous NSCLC with different PD-L1 expression levels`Event-free Survival (EFS)`The Safety and Tolerability...
Trial ID:
Source:
Title:
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Excerpt:
...major pathologic response (MPR) of primary tumor`Perioperative complications`Completion of surgery`Rate of R0 resection`treatment emergent adverse event (TEAE)`Event-free survival (EFS)`Overall survival (OS)`circulating tumor DNA (ctDNA)`Immune subtypes`PD-L1 expression`Tumor mutation burden (TMB)...
Trial ID:
Source:
Title:
Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer.
Excerpt:
...(Phase II)`Number of participants with abnormal vital signs values and/or Adverse Events that are related to treatment.(Phase II)`Number of participants with abnormal ECG and echocardiography values /or Adverse Events that are related to treatment.(Phase II)`Number of participants with aphysical examination values /or Adverse Events that are related to treatment.(Phase II)`ORR in PD-L1 positive and negative populations....
Trial ID:
Source:
Title:
A single-arm, observational, single-center, open label study for PD-1 antibody as a Neoadjuvant therapy for phase IB-IIIA lung squamous cell carcinoma before resectable operation
Excerpt:
...MPR - MPR; PCR - PCR; OS - OS; DFS - DFS; ORR - ORR; PD-L1 expression - PD-L1 expression; WES - WES; RNA-seq - RNA-seq; TCR - TCR; safety - safety...
Trial ID:
Source:
Title:
Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC
Excerpt:
...Treatment-naive, histologically confirmed resectable, stage II, IIIA, IIIB (N2) (AJCC staging system, version 8) NSCLC; cTNM stage can be confirmed through PET-CT or pathological biopsy; resectable stage II non-small cell lung cancer is defined as eligible for radical resection evaluated by a qualified thoracic surgeon; resectable stage III is defined as the resectable and potential resectable according to the Chinese expert consensus on the multidisciplinary diagnosis and treatment for stage III non-small cell lung cancer (2019)in which resectable includes IIIA(N0-1), partial N2 with single-station mediastinal lymph node metastasis and the short diameter of lymph nodepecimens available for pathological diagnosis, detection of PD-L1 expression and biomarkers prior to randomization (the tumor tissue specimens must be freshly obtained or archived samples within 3 months prior to enrollment; tumor tissue specimens must be the samples of histological category, including but...
Trial ID:
Source:
Title:
A single-arm, observational, single-center, open label study for PD-1 antibody as a Neoadjuvant therapy for phase IB-IIIA lung adenocarcinoma before resectable operation
Excerpt:
...MPR - MPR; PCR - PCR; OS - OS; DFS - DFS; ORR - ORR; PD-L1 expression - PD-L1 expression; WES - WES; RNA-seq - RNA-seq; TCR - TCR; safety - safety...
Trial ID:
